BioMarin to buy rare disease drugmaker Amicus for $4.8B

BioMarin is set to acquire Amicus in a $4.8 billion deal. The acquisition provides BioMarin with a late-stage clinical asset and two marketed therapies that generated nearly $450 million in the first nine months of the year.